281 related articles for article (PubMed ID: 18495955)
1. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.
Minard-Colin V; Xiu Y; Poe JC; Horikawa M; Magro CM; Hamaguchi Y; Haas KM; Tedder TF
Blood; 2008 Aug; 112(4):1205-13. PubMed ID: 18495955
[TBL] [Abstract][Full Text] [Related]
2. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy.
Hamaguchi Y; Xiu Y; Komura K; Nimmerjahn F; Tedder TF
J Exp Med; 2006 Mar; 203(3):743-53. PubMed ID: 16520392
[TBL] [Abstract][Full Text] [Related]
3. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.
Tedder TF; Baras A; Xiu Y
Springer Semin Immunopathol; 2006 Dec; 28(4):351-64. PubMed ID: 17091246
[TBL] [Abstract][Full Text] [Related]
4. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.
Uchida J; Hamaguchi Y; Oliver JA; Ravetch JV; Poe JC; Haas KM; Tedder TF
J Exp Med; 2004 Jun; 199(12):1659-69. PubMed ID: 15210744
[TBL] [Abstract][Full Text] [Related]
5. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
[TBL] [Abstract][Full Text] [Related]
6. [Molecular mechanisms of B lymphocyte depletion by CD20 immunotherapy].
Hamaguchi Y
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):29-34. PubMed ID: 19252375
[TBL] [Abstract][Full Text] [Related]
7. Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.
Horikawa M; Minard-Colin V; Matsushita T; Tedder TF
J Clin Invest; 2011 Nov; 121(11):4268-80. PubMed ID: 22019587
[TBL] [Abstract][Full Text] [Related]
8. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Beers SA; French RR; Chan HT; Lim SH; Jarrett TC; Vidal RM; Wijayaweera SS; Dixon SV; Kim H; Cox KL; Kerr JP; Johnston DA; Johnson PW; Verbeek JS; Glennie MJ; Cragg MS
Blood; 2010 Jun; 115(25):5191-201. PubMed ID: 20223920
[TBL] [Abstract][Full Text] [Related]
9. The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
Lykken JM; Tedder TF
Cancer J; 2015; 21(4):351-6. PubMed ID: 26222089
[TBL] [Abstract][Full Text] [Related]
10. Rapid desensitization of mice with anti-FcγRIIb/FcγRIII mAb safely prevents IgG-mediated anaphylaxis.
Khodoun MV; Kucuk ZY; Strait RT; Krishnamurthy D; Janek K; Clay CD; Morris SC; Finkelman FD
J Allergy Clin Immunol; 2013 Dec; 132(6):1375-87. PubMed ID: 24139828
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.
DiLillo DJ; Hamaguchi Y; Ueda Y; Yang K; Uchida J; Haas KM; Kelsoe G; Tedder TF
J Immunol; 2008 Jan; 180(1):361-71. PubMed ID: 18097037
[TBL] [Abstract][Full Text] [Related]
12. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
13. Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo.
Tipton TR; Mockridge CI; French RR; Tutt AL; Cragg MS; Beers SA
Blood; 2015 Dec; 126(24):2643-5. PubMed ID: 26492935
[No Abstract] [Full Text] [Related]
14. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.
Hamaguchi Y; Uchida J; Cain DW; Venturi GM; Poe JC; Haas KM; Tedder TF
J Immunol; 2005 Apr; 174(7):4389-99. PubMed ID: 15778404
[TBL] [Abstract][Full Text] [Related]
15. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.
Beers SA; Chan CH; James S; French RR; Attfield KE; Brennan CM; Ahuja A; Shlomchik MJ; Cragg MS; Glennie MJ
Blood; 2008 Nov; 112(10):4170-7. PubMed ID: 18583569
[TBL] [Abstract][Full Text] [Related]
16. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
[TBL] [Abstract][Full Text] [Related]
17. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
Funakoshi S; Longo DL; Murphy WJ
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
[TBL] [Abstract][Full Text] [Related]
19. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.
Boross P; Jansen JH; Pastula A; van der Poel CE; Leusen JH
Immunol Lett; 2012 Mar; 143(1):44-52. PubMed ID: 22285696
[TBL] [Abstract][Full Text] [Related]
20. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Glorius P; Baerenwaldt A; Kellner C; Staudinger M; Dechant M; Stauch M; Beurskens FJ; Parren PW; Winkel JG; Valerius T; Humpe A; Repp R; Gramatzki M; Nimmerjahn F; Peipp M
Leukemia; 2013 Jan; 27(1):190-201. PubMed ID: 22660187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
